Vir Biotechnology, Inc.

"Parts of your life just disappear from you. I used to go to the mountains and go camping. I can’t do that anymore because I feel so tired.” – person living with hepatitis delta. We were honored to welcome and learn from a person living with hepatitis delta, along with Dr. Nghiem Ha, Assistant Professor of Medicine at #UCSF Viral Hepatitis Center. They courageously shared their personal experiences in navigating the devastating disease with us at our recent All Hands. Our deepest gratitude to them both. “I appreciate that Vir Biotechnology is working towards developing a treatment option for our hepatitis delta patients. Everyone needs to know about this disease, and we all need to galvanize around eradicating hepatitis delta for current and future patients.” – Dr. Ha These personal and professional insights are vital in shaping our understanding as we continue to place patients at the heart of our #delta therapeutic development program.  #HepatitisD #PatientsAreWaiting

"As a kid, I was a very inquisitive person. I constantly asked my dad questions.”     Meet our Chief Scientific Officer Jennifer Towne, Ph.D., one of the brilliant minds driving innovation at #VirBiotechnology! She embodies our commitment to both scientific advancement and fostering talent.      This International Day of Women and Girls in Science, we’re proud to celebrate the achievements of Jennifer and other inspiring women on our teams. Their contributions are invaluable to our mission of powering the immune system to transform lives. Learn more about her https://bit.ly/4gDXFoC #WomeninSTEM #WomeninScience #InternationalDayofWomenandGirlsinScience2025    

AI may be a hot topic right now, but at #VirBiotechnology it's an integral part of how we work. Ramy Farid, Ph.D., from our Board of Directors and CEO of #Schrödinger, recently joined our CEO Marianne D. De Backer, MSc, PhD, MBA, for a discussion about how to bring meaningful change in today’s AI-driven landscape and what sets us apart. Our team enjoyed the opportunity to dive into the possibilities of how we can take our work with AI to the next level and the impact its already having each day. Learn how we’re leveraging our deep expertise in biology with our AI engine, #dAIsY™, to accelerate the discovery and development of lead drug candidates with the highest potential for success. https://bit.ly/4f490Oy

To participate in a clinical trial takes a leap of faith for people living with cancer, their families and their physicians. This World Cancer Day, we thank everyone in our clinical studies as we work to offer new hope for people living with solid tumors. At #VirBiotechnology, we recognize every experience with cancer is unique. We’re determined to keep listening to the unique perspectives from across the community to ensure the #PatientVoice informs our programs at every stage of the development process, in our shared goal to overcome cancer. #UnitedbyUnique #WorldCancerDay #ClinicalTrials #Gratitude #PatientsAreWaiting Union for International Cancer Control (UICC)

📣 The future leaders of biotech are coming! We are pleased to kick off our San Francisco State University Mentorship Program for 2025! This critical program connects STEM students with knowledge and coaching to thrive in biotech. 🚀 We’re fortunate to collaborate with the next generation of innovators – sharing ideas and helping us build a more inclusive future in science! #STEM #Mentorship #DiversityinTech #SFSU

We're encouraged by the shared excitement around our recent data and its potential to offer new hope for people living with cancer. "Early data from our T-cell engager candidates suggest the dual-masking approach can significantly widen the therapeutic index based on showing encouraging signs of anti-tumor activity at well tolerated doses for patients who need new options to treat their cancers.” – Mika Kakefuda Derynck, M.D., EVP, Therapeutic Area Head Oncology at #VirBiotechnology. 🎯Our investigational dual-masked T-cell engagers, VIR-5818 and VIR-5500, target two proteins with crucial roles in cancer: HER2 and PSMA, respectively. VIR-5818 is currently being studied across a variety of solid tumors, including breast and colorectal cancer, and VIR-5500 is being studied in metastatic castration-resistant prostate cancer. Learn more ➡️ https://bit.ly/4gKXbxX

With #JPM25 wrapping up, it’s time to reflect on what has been a thrilling week for Vir Biotechnology. ⚕️We kicked-off with new data from our ongoing Phase 1 studies with two investigational dual-masked TCEs, showcasing their potential to improve outcomes for #cancer patients. 🤝 Our team met with investors and collaborators to discuss how we can best accelerate innovation in both cancer and infectious diseases. 📈 We presented our strategy for executing on our mission to power the immune system to transform lives through advancing key strategic priorities. 📢 Learn more about us, our mission and our priorities for 2025 here: https://bit.ly/40648m1 #PatientsAreWaiting #Oncology #InfectiousDiseases

Join us at #JPM25! We’ll discuss our investigational pipeline that includes advanced hepatitis delta and B regimens as well as three dual-masked T-cell engagers. Find out how our strategic efforts in #oncology and infectious disease are geared to harness the power of the immune system to positively transform the lives of patients and their families. https://bit.ly/40648m1 #PatientsAreWaiting #HepatitisDelta #HepatitisB #Cancer

Our CEO Marianne D. De Backer, MSc, PhD, MBA, joined an insightful panel at Longwood Healthcare Leaders to discuss what is next in developing targeted therapies in #oncology.     Marianne highlighted the potential of masked T-cell engagers in cancer therapy and the emerging role of new technology such as the protease-cleavable masking platform to improve targeting. The panel also discussed the importance of innovative approaches in potentially improving patient outcomes and reducing off-tumor toxicity.    #PatientsAreWaiting #Cancer #TCellEngagers #LongwoodHealthcareLeaders #JPM25 

At Vir Biotechnology, 2025 is a year of immense opportunity to advance investigational #oncology and infectious disease medicines for patients – with determination and speed. Join us and Marianne D. De Backer, MSc, PhD, MBA at #JPM25 to hear more about our clinical pipeline focused on powering the immune system to transform lives. https://lnkd.in/enhjWCh7 #PatientsAreWaiting #InfectiousDisease #Cancer